Fabrazyme (agalsidase beta)
Phase 3Completed 0 watching 0 views this week📈 Rising
76
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Fabry Disease
Conditions
Fabry Disease
Trial Timeline
Oct 1, 1999 → Dec 1, 2004
NCT ID
NCT00074971About Fabrazyme (agalsidase beta)
Fabrazyme (agalsidase beta) is a phase 3 stage product being developed by Sanofi for Fabry Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT00074971. Target conditions include Fabry Disease.
Hype Score Breakdown
Clinical
27
Activity
18
Company
9
Novelty
9
Community
10
Clinical Trials (4)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00312767 | Approved | Withdrawn |
| NCT00196716 | Phase 2 | Completed |
| NCT00074958 | Phase 2 | Completed |
| NCT00074971 | Phase 3 | Completed |
Competing Products
20 competing products in Fabry Disease
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Lucerastat | Idorsia | Phase 3 | 72 |
| Fabrazyme (agalsidase beta) | Sanofi | Phase 2 | 51 |
| Venglustat (GZ402671) + Placebo | Sanofi | Phase 3 | 76 |
| Fabrazyme (agalsidase beta) + Fabrazyme (agalsidase beta) | Sanofi | Phase 2 | 51 |
| agalsidase beta | Sanofi | Approved | 84 |
| Tropicamide | Sanofi | Pre-clinical | 22 |
| Fabrazyme (agalsidase beta) | Sanofi | Approved | 84 |
| agalsidase beta | Sanofi | Approved | 84 |
| AGALSIDASE BETA (GZ419828) + Acetaminophen + Diphenhydramine + Dexamethasone + Montelukast + Loratadine + Cetirizine + Fexofenadine | Sanofi | Approved | 84 |
| Gabapentin + placebo | Sanofi | Phase 2 | 51 |
| Agalsidase beta | Sanofi | Approved | 84 |
| GZ/SAR402671 | Sanofi | Phase 2 | 51 |
| agalsidase beta (GZ419828) + agalsidase alfa | Sanofi | Approved | 84 |
| Venglustat (GZ402671) + Agalsidase alfa + Agalsidase beta (GZ419828) + Migalastat | Sanofi | Phase 3 | 76 |
| Iohexol | Sanofi | Phase 1 | 32 |
| GZ/SAR402671 | Sanofi | Phase 2 | 51 |
| Fabrazyme (agalsidase beta) | Sanofi | Phase 2 | 51 |
| Agalsidase beta | Sanofi | Approved | 84 |
| Fabrazyme (agalsidase beta) + Placebo | Sanofi | Approved | 84 |
| Agalsidase beta + Agalsidase beta | Sanofi | Phase 3 | 76 |